Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A071102
  • The purpose of this study is to compare the effects, good or bad of the usual treatment (known as temozolomide) with or without the addition of the research drug veliparib for people whose brain tumors show a change in a small region of DNA (or gene) called O6-methylguanine methyltransferase (called MGMT).

  • Alliance A071401
  •  The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, treatment for meningioma is the same for all patients, and is not based on tumor genetic testing. This study is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you.

  • Alliance A221208
  • Usually the first treatment for brain radionecrosis only works for some patients and can cause significant side effects in many patients. The purpose of this study is test whether adding a drug called bevacizumab to your standard corticosteroid therapy will improve your symptoms over corticosteroid therapy alone by improving the radionecrosis and minimizing treatment-related side effects. The effects of bevacizumab with standard corticosteroid therapy will be compared to a placebo with standard corticosteroid therapy.

  • NRG CC001
  • The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation plus memantine to using the usual whole-brain radiation plus memantine.  The hippocampus is a brain structure that is important for memory.  The addition of the hippocampal avoidance technique to the usual whole-brain radiation plus memantine will decrease the dose of radiation to your hippocampus. It is hoped hippocampal avoidance technique will decrease the chance of cognitive side effects, however it is possible hippocampal avoidance could have no impact on cognitive side effects and could even cause side effects.   

  • NRG/RTOG 1122
  • The purpose of this study is to find out the effect of bevacizumab with or without a new research drug, AMG 386, on glioblastoma or gliosarcoma. Bevacizumab is a protein that works by preventing new cancer-related blood vessel formation. The U.S. Food and Drug Administration (called FDA) has approved bevacizumab for the treatment of recurrent glioblastoma. However, treatment with bevacizumab alone has only modestly improved overall survival in patients with this type of brain tumor. For this reason other drugs, such as AMG 386, are being evaluated.